Velpatasvir Production Cost Reports

The report provides a detailed analysis essential for establishing a Velpatasvir production plant. It encompasses all critical aspects necessary for Velpatasvir production, including the cost of Velpatasvir production, Velpatasvir plant cost, Velpatasvir production costs, and the overall Velpatasvir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Velpatasvir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Velpatasvir is a medicine used to treat hepatitis C, which is a virus that affects the liver. It is given as a single pill combined with another medicine called sofosbuvir. It is commonly administered as a fixed-dose combination with sofosbuvir. This combination is recommended as first-line therapy for chronic hepatitis C patients with or without compensated cirrhosis, and in some cases, with ribavirin for decompensated cirrhosis. It works by stopping the protein, which is essential for viral replication. Its high barrier to resistance makes it a potent and reliable option compared to earlier inhibitors. It also shows a favourable drug-drug interaction profile, making it suitable for patients with comorbidities and those on other medications.

The market for Velpatasvir is driven by the increasing global prevalence of chronic hepatitis C. The growing awareness of hepatitis C among healthcare providers and patients, along with government programs aimed at removing the disease, fuels its demand. Its usage in combination with sofosbuvir, because of its high effectiveness and minimal side effects, makes it a preferred treatment option. The urgent need for better antiviral therapies, the expansion of healthcare infrastructure in developing regions, and ongoing research that introduces new combination treatments boost its demand. The industrial Velpatasvir procurement is influenced by pricing and reimbursement policies, availability of generic versions, regulatory approvals, supply chain robustness, and access programs by pharmaceutical companies.

Raw Material for Velpatasvir Production

According to the Velpatasvir production plant project report, the key raw materials used in the production of Velpatasvir include Intermediate VP4-Tetrahydrofuran- 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)-Glacial Acetic Acid.

Production Process of Velpatasvir

The extensive Velpatasvir production cost report consists of the following major industrial production process:

1. From Intermediate VP4: The production process of Velpatasvir starts by dissolving intermediate VP4 in tetrahydrofuran and cooling it to 0-5 degree Celsius. To this glacial acetic acid is added, followed by a tetrahydrofuran solution of DDQ dropwise. The reaction mixture is neutralised with sodium hydroxide solution. Now, water and dichloromethane are added, the layers are separated, and the aqueous layer is extracted with dichloromethane multiple times. The combined organic layers are washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate to get a crude solid product. This crude is recrystallised from isopropanol and water to obtain Velpatasvir as the final product.

Velpatasvir has the molecular formula C49H54N8O8 and a molecular weight of 883 g/mol. It is a heteropentacyclic compound characterised by multiple nitrogen and oxygen atoms and aromatic rings. It has a relatively high lipophilicity with a LogP value around 6.2, indicating it is more soluble in lipids than in water, which supports good absorption when taken orally. It has four hydrogen bond donors and eight acceptors, and its structure involves multiple rings that contribute to its biological activity. It has a melting point above 170 degree Celsius. It is sparingly soluble in water but dissolves well in organic solvents like DMSO. It is highly bound to plasma proteins and metabolised slowly by liver enzymes, allowing it to be administered once daily. These physical and chemical properties make it useful as a direct-acting antiviral used in combination therapy for hepatitis C treatment.